Ajanta Pharma Ltd. News and Updates

Name: Latest research reports of Ajanta Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Ajanta Pharma Ltd. from all sources in a single place.

Load latest

Ajanta Pharma Ltd.

08 May 2022

2766.00

1.91%

Pharma stock to consider bonus shares issue next week. Details inside

livemint

Ajanta Pharma's board will meet next week on May 10 to consider bonus shares issue along with its financial results

Ajanta Pharma Ltd. is trading above its 50 day SMA of 2669.0

Ajanta Pharma Ltd.

06 May 2022

2766.00

1.91%

Pharma stock to consider bonus shares issue next week. Details inside

livemint

Ajanta Pharma's board will meet next week on May 10 to consider bonus shares issue along with its financial results

Ajanta Pharma Ltd. is trading below its 100 day SMA of 2799.7

Ajanta Pharma Ltd.

02 May 2022

2766.00

1.91%

Market movers: Why Ajanta Pharma & Meghmani Organics surged up to 12%

Economic Times

The company in a regulatory filing said the Board of Directors of the Company will meet on Tuesday, 10th May 2022 to inter-alia considerissue of bonus shares subject to approval by the shareholders of the company.

Ajanta Pharma Ltd. is trading below its 100 day SMA of 2799.7

Ajanta Pharma to consider bonus share issue, board meet next week

livemint | 02 May 2022

Ajanta Pharma Ltd.

16 Apr 2022

2766.00

1.91%

Why you should buy Ajanta Pharma shares

Business Line

Established operations in high-growth markets with better pricing power is a positive for the stock trading at 1725 levels

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

24 Mar 2022

2766.00

1.91%

Broker's call: Ajanta Pharma (Buy)

Business Line

Motilal Oswal

Ajanta Pharma Ltd.'s price crossed above 50Day SMA today

Ajanta Pharma Ltd.

22 Mar 2022

2766.00

1.91%

Robust outlook in the Branded Generics segment

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

AJP delivered 13% sales CAGR from Dec'18 to Dec'21, led by steady traction in existing therapies and ramp-up in newly added therapies and the Trade Generics segment. It delivered a sales growth of 23% YoY to INR7.3b (30% of sales) in 9MFY22. With the easing of COVID-19 cases, doctor-patient connectivity has significantly improved, particularly in the Ophthalmology/Dermatology segment (39% of DF sales in 9MFY22). This bodes well for better growth prospects for AJP. This, along with enhanced marketing efforts in the Cardiology segment (~41% of DF sales in 9MFY22)...

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

10 Mar 2022

2766.00

1.91%

Buy Ajanta Pharma; target of Rs 2400: Ajcon Global

Moneycontrol

Ajcon Global is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its research report dated March 08, 2022.

Ajanta Pharma Ltd. has gained 28.51% in the last 1 Year

Ajanta Pharma Ltd.

03 Feb 2022

2766.00

1.91%

Buy Ajanta Pharmaceuticals; target of Rs 2605: ICICI Direct

Moneycontrol

ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2605 in its research report dated February 02, 2021.